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Iminunoreactive and bioactive luteinizing hormone in pubertal patients
with chronic renal failure. Disturbed pulsatile LH secretion has been
suggested to play a role in the etiology of delayed puberty and disturbed
reproductive function in chronic renal failure (CRF), but interpretation
of gonadotropin secretion from plasma concentration measurements is
confounded by alterations in hormone metabolic clearance. To simul-
taneously investigate LH secretion and clearance in children, we
performed multiple-parameter deconvolution analysis of 11-hour over-
night serum LH concentration-time series of bioactive (bio-LH) and
immunoreactive (i-LH) hormone in 36 pubertal patients (18 boys) with
various degrees of CRF and 10 healthy controls matched for sex and
pubertal stage. Twelve patients received conservative treatment for
advanced but compensated CRF, 12 were treated by dialysis, and 12
were studied after successful renal transplantation. We observed that:
(1) the mean (± SE) plasma half-lives of bio-LH and i-LH were
increased in the dialysis group (155 47 and 201 31 mm) and in the
patients on conservative treatment (148 45 and 135 70 mm)
compared to controls (59 28 and 63 21 mm; all P < 0.05). The
plasma half-life of bio-LH in patients on conservative treatment or after
renal transplantation was inversely correlated with glomerular filtration
rate (GFR) (r = —0.70; P < 0.0001). (2) Pulsatile bio-LH production
rate was independently affected by pubertal stage (P = 0.018) and
treatment status (P = 0.017), increasing across pubertal stages and
being significantly lower in dialysis patients (20 4 lU/liter * 11 hr) and
patients on conservative treatment (28 9) than in controls (43 9; all
P < 0.05). In patients on conservative treatment or after transplanta-
tion, a significant positive correlation between pulsatile bio-LH produc-
tion rate was observed (r = 0.53; P < 0.008). Pulsatile i-LH secretion
rate was significantly reduced only in dialysis patients (15 34 vs. 46
18; P < 0.05). (3) The reduction of pulsatile i-LH andlor bio-LH
production rates was attributable to a halving of the LH mass secreted
per burst in patients on conservative (bio-LH: 4.9 1.9 lU/liter) and
dialysis treatment (bio-LH: 3.2 0.7, i-LH: 2.4 0.6 lU/liter) versus
controls (bio-LH: 6.9 1.3, i-LH: 5.4 2.1 lU/liter), whereas the LH
pulse frequency was not different between controls and treatment
groups. (4) The relative contribution of apparent basal LH release to
total secretion rates was higher (25 11%) in patients on dialysis than
in controls (6.8 3.9%; P <0.0.05). (5) Mean plasma concentrations of
i-LH, but not bio-LH, were significantly elevated in the uremic chil-
dren. The reduction of mean bio-LH/i-LH ratio in the uremic children
was due to the relative increase in basal i-LH secretion, resulting in a
significant reduction of the bio-LH/i-LH ratio of total LH secretion
rates in patients on conservative treatment (1.14 0.2 vs. 2.2 0.2)
and dialysis (1.5 0.24), whereas the bio-LHIi-LH ratio of plasma
half-lives was similar (dialysis) to controls or even increased (conser-
vative treatment). In the transplant patients, none of the secretory and
clearance characteristics was significantly different from controls. In
conclusion, the secretory pattern of LH in uremic pubertal children is
characterized by a distinct increase in plasma half-life, and a reduction
of the LH secretion rate compatible with deficient GnRH signal strength
and/or pituitary responsiveness. Possibly due to accumulation of as yet
undefined immunoreactive but biologically inactive LH fragments,
apparent basal secretion of i-LH but not bio-LH is relatively increased
in dialyzed patients, resulting in a disproportionate increase of i-LH
compared to bio-LH mean plasma concentrations.
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Disturbed sexual function is a common complication of
chronic renal failure (CRF). Patients with childhood onset of
CRF frequently show delayed onset and/or disturbed progress
of sexual maturation [1, 2]. Adult patients with CRF commonly
exhibit disorders of libido, potentia and fertility, frequently
associated with testicular atrophy in men and menstrual disor-
ders in women [31.
Previous investigations of the endocrine status of patients
with CRF revealed normal or elevated serum immunoreactive
gonadotropin concentrations, a blunted or prolonged apparent
responsiveness of the pituitary to stimulation by exogenous
GnRH and, in male patients, a reduced functional reserve of the
Leydig cells in reponse to HCG stimulation [4—8]. More re-
cently, studies of gonadotropin concentration profiles have
inferred a reduced frequency of secretory episodes of LH in
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Table 1. Clinical characteristics of 36 patients with chronic renal failure and 10 controls
Conservative
treatment Dialysis Transplantation Controls
Tannerbreaststage 223335 233344 223455 22355
Tannergenitalstage(boys) 223455 223344 234455 22345
Testicular volume
4—6/7—l0/>lOml 3/1/2 2/3/1 2/2/2 2/1/2
Age years
Boys 14.3 0.8 (138)b 14.7 1.1 (14.3) 15.0 0.8 (15.4) 14.6 0.8 (13.9)
Girls 14.6 1.4 (136)b 15.9 1.1 (15.2) 15.4 1.2 (15.5) 12.6 0.3 (12.4)
RUS bone age years
Boys 12.4 0.7 (125)b 12.6 0.8 (12.5) 13.2 1.1 (13.7)
Girls 13.0 0.8 (129)b 13.9 0.4 (13.9) 14,7 0.5 (14.5) *
GFR mI/mm/i .73 m2
Boys 23 4.1 (19) — 67 7.2 (65)
Girls 23 3.2 (22) — 68 13 (72)
Data are mean SEM (median). Symbol is:
* No data are available.
a Significantly different from transplant group (P < 0.001)b No significant differences between groups within a row
adults [9—11] and pubertal children [12, 13] with end-stage CRF.
Reduced incremental amplitudes of the secretory pulses were
also found by some authors [11, 13]. Furthermore, reduced LH
bioactivity in relation to immunoreactivity and a dissociation of
serum immunoreactive (i-) and bioactive (bio-) LH concentra-
tion pulses were observed in adult [11] and adolescent [13, 14]
dialysis patients. These changes appear to be reversible after
successful renal transplantation.
Since pulsatile LH secretion is believed to reflect the pattern
of hypothalamic GnRH release [15], and bioactive LH is
preferentially released in normal men during the secretory
episodes [16, 17], both reduced pulse frequency and decreased
bloactivity of LH have been speculated to reflect an alteration
of the hypothalamic GnRH pulse generator in CRF. Since the
emergence of a pulsatile pattern of GnRH and LH release is the
key endocrine event triggering normal sexual maturation, reg-
ulatory failure at this level may be the primary pathophysiolog-
ical mechanism for pubertal delay or arrest in adolescents with
severe CRF.
On the other hand, pulse detection may be confounded by a
decrease in metabolic clearance rate reported for LH and other
glycoprotein hormones in uremic animals [18, 19] and humans
[4]. An increase in plasma half-life may either mask true
secretory episodes in plasma concentration profiles or facilitate
erroneous identification of random measurement variation as
peaks [20, 21]. In pubertal patients, physiological developmen-
tal changes in gonadotropin peak frequency and/or amplitude
must be differentiated from disease effects. We have therefore
assessed possible neuroendocrine changes of the hypothalamo-
pituitary-gonadal axis during puberty in uremic individuals by:
(1) studying, in a inulticenter effort, a sufficiently large, control-
matched sample of patients at different stages of puberty and
renal dysfunction; (2) using deconvolution analysis [22] to
differentiate and quantitate LH secretion and metabolic clear-
ance rates in uremia; and (3) determining LH concentrations by
radioimmunoassay and an in vitro bioassay to study the mech-
anisms of a possible dissociation between bioactive and immu-
noreactive LH plasma concentrations in uremia.
Methods
Study patients
LH secretion and clearance was determined in 36 pubertal
patients with different degrees of CRF and 10 controls matched
for sex and stage of pubertal development. Twelve patients, six
of either sex, were studied in each of the following treatment
groups: (i) conservative treatment for advanced but compen-
sated CRF; (ii) chronic maintenance (hemo- or pentoneal)
dialysis for end-stage CRF; (iii) renal transplantation. For the
combined groups of patients on conservative and dialysis
treatment, the term 'uremic patients" is used in the following.
The patient hormone profiles were selected, stratified for sex
and pubertal stage, from the longitudinal Cooperative Study on
Pubertal Development in Chronic Renal Failure [23]. The 10
control children (5 boys) were nondiabetic siblings of children
with juvenile diabetes mellitus [24]. Basic clinical data including
pubertal stages according to Tanner [25] and orchidometry are
given in Table 1. Skeletal maturation was assessed in the patient
groups by the Tanner-Whitehouse II method [26]. Underlying
renal diseases were renal dysplasia or hypoplasia (N = 10),
obstructive and/or reflux uropathy (N = 8), focal-segmental
glomeruloscierosis (N = 7), rapidly progressive glomerulone-
phritis (N = 3), other chronic glomerulopathies (N =2), chronic
interstitial nephritis (N = 3), and others or unknown (N = 3).
Glomerular filtration rate (GFR) was calculated according to the
formula: serum creatinine * 0.55/height. Most patients required
antihypertensive treatment, comprising f3-blocking agents (N =
13), Ca channel blockers (N = 8), vasodilating agents (N = 3),
and angiotensin-converting enzyme inhibitors (N 2). The
distribution of the antihypertensive medications was similar in
the different treatment groups. Transplant patients received
immunosuppression with cyclosporin A (N = 8), azathiopnne(N = 8) and methylprednisolone or prednisone (N = 12). The
regular drug schedule was followed on the study day.
Approval for the study was obtained from the local ethical
comittees at each participating pediatric nephrology center
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(patients) and at Oxford University (controls). All parents
signed informed consent.
Study protocol
The subjects were admitted to the hospital for an overnight
stay. An intravenous cannula was inserted in the forearm at
19.00 hours. Blood was withdrawn from 20.00 to 07.00 hours at
15 minute intervals. The total amount of blood withdrawn
during a study was approximately 70 ml. Sleep was monitored
visually. In hemodialysis patients the study was performed in
the night preceding a hemodialysis session. The patients on
continuous ambulatory or cyclic peritoneal dialysis continued
their regular fluid exchanges during the study.
Immediately after the study, serum was stored at —20°C until
assay. I-LH and bio-LH concentrations were determined in
each sample. Gonadal steroid hormones, that is, testosterone in
boys and estradiol in girls, were measured at hourly intervals;
the peak nocturnal plasma concentrations were used for com-
parison between control and treatment groups.
Assays
i-LH was measured using a polyclonal RIA (Chelsea Re-
agents, Hammersmith Hospital, London, UK) modified with a
sac-cel (IDS Ltd, Tyne & Wear) separation step. All samples in
an overnight study were assayed in duplicate within the same
batch. The lower detection limit of the assay was 0.9 lU/liter.
Free a-subunit cross-reactivity with the LH antiserum was
< 0.1% [27]. The mean intra-assay coefficients of variation
(CV), determined from > 400 duplicate pairs per concentration
interval, were 9.0, 5.2, 4.8 and 5.4% at 1.9, 5.5, 11.0, and 31.0
lU/liter, respectively. The interassay CV of four quality control
sera was < 8% at all dose levels.
LH bioactivity (bio-LH) was measured using an in vitro
bioassay based on the dispersed mouse Leydig cell assay [281
modified by us [291. Serum samples were diluted in Dulbecco's
Modification of Eagles Medium (DMEM) containing 20 mM
Hepes (Northumbria Biologicals, Cramlington, Northumbria,
UK) and assayed at various concentrations between 8% (1/12.5)
and 1% (1/100). All samples from the same subject were assayed
within a single batch to eliminate between-assay variability.
Following the incubation, single samples were removed from
duplicate wells for each diluted standard, serum and quality
control sample, and measured by an in-house non-extracted
testosterone endpoint RIA at a dilution of 1/20 (DMEM + 0.1%
BSA). This ensured that samples fell into the most precise
region of the standard curve, which typically returned an
intra-assay CV of < 3%. The working range of this assay was 1
to 128 nmollliter and had a between-assay precision of < 10%.
The testosterone produced in each sample well was then
compared to that obtained by a calibration curve composed of
increasing concentrations (0.15 to 2.0 lU/liter) of the same
international standard as that used for the RIA. The estimate of
bio-LH obtained was consequently reported in lU/liter. The
absolute detection limit of this assay was 0.15 lU/liter defined as
the concentration of LH which yielded a testosterone produc-
tion which was consistently higher (> 2 SD) than the basal
testosterone secretion in every bioassay. The limit of detection
of the bioassay was 1.9 lU/liter, defined as the absolute bioas-
say sensitivity (0.15 lU/liter) multiplied by the lowest dilution
factor used (8%). Every tenth patient sample and quality
control sera were assayed at two different dilutions in order to
assess assay parallelism which was conserved in all cases (CV
< 15%). The between assay precision, based on three quality
control sera of 5.0, 15 and 70 lU/liter tested in consecutive
assay, was < 10% at all dose levels. A fourth quality control
comprised serum which had been incubated with solid phase
bound antiserum to immunoabsorb the LH, yielded a value of
< 1.9 lU/liter in every assay. The interassay precision quoted
below reflects the variability of the whole bioassay system, that
is, that of the bioassay and the endpoint assay combined for
patient sera estimated at a single plasma dilution. Intra-assay
precision, based on a large number of similar serum samples,
was typically 5.0% (1.9 to 5.0 lU/liter, N = 216), 3.9% (5.1 to 10
lU/liter, N = 1345), 5.7% (10.1 to 20 lU/liter, N = 286), 5.8%
(20.1 to 40 lU/liter, N = 262), 5.6% (40.1 to 80 lU/liter, N =
189), 7.2% (> 80 lU/liter, N = 65). Using the method of
Lambert, Mitchell and Robertson [30], no interference with the
assay system was found with the immunosuppressive drugs
cyclosporin A, azathioprine and methyl-prednisolone at con-
centrations of up to 10 times the upper limit of the blood
therapeutic range.
Plasma testosterone and estradiol were measured by using
in-house RIAs. Plasma testosterone was determined after an
extraction step. Interassay CVs were < 15% and intra-assay
CVs 5 to 10% within the measured concentration ranges.
Deconvolution modeling
The aim of multiparametric deconvolution modeling is the
quantitative estimation of various specific measures of hormone
secretion and clearance using all sample hormone concentra-
tions and their intra-assay variances considered simulta-
neously. We calculate individual secretory properties, which,
when combined with subject-specific clearance kinetics, give
rise to the observed time series of plasma hormone concentra-
tions. Such computations assume that plasma hormone concen-
trations are determined by: (1) the number, (2) the amplitudes,
and (3) the durations of all prior secretory impulses, acted upon
by (4) endogenous subject-specific clearance kinetics. In addi-
tion, the possibility of basal (tonic) hormone release was
allowed for by inclusion of a respective term into the model.
The mathematical formulation of this model has been summa-
rized elsewhere [22]. The following secretion and clearance
values were estimated in each i-LH and bio-LH time-series: the
plasma disappearance ha1f-lfe, calculated according to a
monocompartment model (as validated earlier [31]) from the
plasma hormone decay curves following each secretory im-
pulse; the number, amplitude (that is, maximal secretion rate
during a secretory burst) and half-duration (that is, burst
duration at half-maximal amplitude) of the secretory impulses;
and the mass of hormone secreted per burst (given by
* burst SD * burst amplitude). The pulsatile hormone se-
cretion (or production) rate is the total hormone mass released
within (pulsatile) secretory events during a profile. The basal
hormone secretion rate reflects circulating hormone that cannot
be attributed to pulsatile secretion. The total hormone secretion
(or production) rate is the sum of the pulsatile and basal
secretion rates.
The applicability of the deconvolution methodology in the
present sample of uremic and healthy subjects was validated by
analysis of 20 synthetic data series simulating 11-hour LH
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Table 2. Plasma hormone concentrations in patients with chronic renal failure and healthy control children
Conservative treatment Dialysis Transplantation Controls
Mean i-LH lU/liter
Boys
Girls
6.3
6.7
0.3 (6.2)a
1.7 (6.9)a A
6.5 1.0 (6.3)a
9.7 1.9 (9.8)a A
6.5 0.7 (6.7)a
5.8 0.8 (61)ab
A 2.6 0.5 (2.6)t
3.5 0.7 (29)b
Mean bio-LH lU/liter
Boys
Girls
9.5
9.7
1.1 (10.5)"
3.1 (9.2)"' N
9.9 2.5 (8.4)
13.0 4.3 (9.3)
10.9 0.8 (9.3)
9.9 1.2 (5.7)
6.0 1.6 (6.3)
8.5 2.3 (7.2)
Peak testosterone ngldl, boys
Peak estradiol pg/mi, girls
292
21
64 (230)
6.7 (16)
NS
NS
271 96 (304)
70 27 (56) 367 51(306)67 23 (52)
440 222 (126)
86 44 (90)
Data are mean SEM (median). Letters indicate significant differences between columns within each row, groups with common letters not
differing significantly. Superscript letters give significances for sex subgroups; capital letters for sexes combined. NS means no significant
differences within a row. Significance level is P < 0.05.
concentration profiles sampled at 15 minute intervals, encom-
passing interburst-intervals of 90 18 minutes, secretory burst
amplitudes of 0.42 0.08 lU/liter * mm and plasma half-lives
ranging from 30 to 290 minutes. Secretory events were detected
with a sensitivity of 99.3% and a specificity of 91.0%. Positive
and negative accuracy were 91.8% and 99.2%, respectively.
The correlation coefficient between the predicted and known
(synthetic) half-lives was +0.94 (P < 0.0001).
Statistics
Logarithmic transformation of the data was performed before
statistical testing for those parameters which were not normally
distributed as defined by the Shapiro-Wilk test (secretion pa-
rameters).
Analysis of variance (ANOVA) was carried out using 'treat-
ment' status (that is, conservative treatment, dialysis, trans-
plantation or control), sex, pubertal (Tanner Breast/Genital)
stage and "center" as potential main effector variables [32]. In
addition, a nested effect of treatment status within the pubertal
stage variable was evaluated by a nested design ANOVA [32].
Duncan's test for multiple comparisons was performed to check
for significant differences between the treatment and control
groups. Stepwise multiple regression analysis was used to
evaluate the relative contribution of pulsatile and basal secre-
tion rates and plasma half-life to mean plasma LH concentra-
tions. Associations between variables were evaluated by calcu-
lation of Spearman correlation coefficients.
Results
As summarized in Table 2, mean plasma concentrations of
i-LH were significantly elevated in all treatment groups com-
pared to controls, whereas the differences were not significant
for bio-LH. Consequently, the ratio of bio-LH to i-LH mean
concentrations was significantly reduced in patients on conser-
vative treatment (1.35 0.13), dialysis (1.24 0.11) and after
transplantation (1.57 0.18) compared to controls (2.25 0.19,
differences P < 0.05). Peak nocturnal sex steroid concentra-
tions did not differ significantly between patients and controls.
In Figure 1, the technique of deconvolution analysis is
illustrated in representative examples of pulsatile profiles of
i-LH and bio-LH concentrations from one individual in each
group. The upper panels depict the original plasma LH concen-
tration values with the best-fitting concentration-time curves
estimated by deconvolution, and the lower panels the calcu-
lated pituitary LH secretion rates. Continued pulsatile LH
secretion was observed in uremic patients, albeit typically in
reduced amounts (below).
The statistical results of deconvolution analysis are summa-
rized in Tables 3 and 4. Since none of the secretory and
clearance characteristics was significantly affected by sex (see
below), statistical results are given for both sexes combined.
None of the parameters examined was significantly influenced
by a center effect.
We observed a two- to fourfold prolongation of calculated
plasma half-life of both i-LH and bio-LH in the uremic patient
groups compared to controls. i-LH, but not bio-LH half-life was
significantly longer in patients on dialysis than in the conserva-
tive treatment group. Plasma LH half-lives in the transplant
group did not differ significantly from values in controls. When
the patients on conservative treatment and after transplantation
were considered together as a group of subjects with variably
reduced renal function, a significant inverse relationship was
observed between glomerular filtration rate and the plasma
half-life of bio-LH (r =
—0.70; P < 0.0001). As shown in Figure
2, the relationship could be best approximated by an exponen-
tial function.
The major part of the total i-LH and bio-LH production rate
was accounted for by pulsatile secretion. However, in 16 of the
36 i-LH and 17 of the 36 bio-LH concentration profiles, signif-
icant non-pulsatile (tonic) "basal secretion" could be fitted in
addition to the episodic secretory bursts. ANOVA (testing for
main effects) revealed that the pulsatile bio-LH production rate
was affected by pubertal stage (P = 0.018) and treatment status
(P 0.017), but not by sex (P = 0.53). Application of a
"nested" design (treatment within pubertal stage) showed a
significant effect of treatment on pulsatile bio-LH production
rate at each level of pubertal maturation (P = 0.037). With
regard to the total bio-LH secretion rate (sum of pulsatile and
"basal" secretion), the treatment status was found to have a
main effect (P = 0.008), but the effect of puberty was only of
borderline significance (P = 0.07), suggesting that the basal
secretion component was independent of the stage of pubertal
maturation. A highly significant nested effect of treatment
status within the puberty variable (P = 0.006) was oberved for
total bio-LH secretion.
The total (P 0.04) and pulsatile i-LH production rates (P =
0.009) were significantly affected by treatment, but not by
pubertal stage or sex. Duncan's testing (Tables 3 and 4)
identified a significant reduction of the total and pulsatile
bio-LH production rate in the conservative treatment and
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dialysis groups, and of the pulsatile, but not total i-LH produc-
tion rate in the dialysis group. The pulsatile secretion rates of
both i-LH and bio-LH were approximately halved in dialysis
patients compared to controls. In contrast, neither pulsatile nor
total i-LH and bio-LH production in the transplant group
differed significantly from corresponding values in controls.
Analysis of the combined group of patients on conservative
treatment and after renal transplantation revealed a significantly
positive relationship between pulsatile bio-LH production rate
and glomerular filtration rate (r 0.53; P = 0.008).
Since neither i-LH nor bio-LH pulse frequency differed
significantly between the treatment and control groups, the
reduced pulsatile LH production rate in uremic patients was
entirely attributable to a decrease in secretory burst mass,
which was significant in dialysis patients for i-LH and bio-LH,
and for bio-LH in patients treated conservatively. The mass of
hormone secreted per burst is proportional to the half-duration
and the amplitude of the secretory burst. The decrease in
bio-LH burst mass in the uremic patients was mediated by a
decrease in burst amplitude (significant for dialysis patients),
whereas burst half-duration was unchanged in dialysis patients
and even elevated in patients on conservative treatment. For
i-LH, no homogenous pattern of change in secretory burst
dynamics could be differentiated.
Although the differences in absolute "basal secretion" rates
did not reach significance between the groups, apparent basal
secretion of i-LH tended to be higher in the dialysis group, and
that of bio-LH tended to be lower in the uremic groups than in
the normal controls. The mean (± SE) fraction of total i-LH
secretion accounted for by "basal secretion" was 25 11% in
the dialysis group compared to 6.8 3.9% in the controls (P <
0.05). In contrast, "basal secretion" of bio-LH constituted a
fraction of 19 9% in the dialysis and 9.5 6.9% in the
conservative treatment group, as compared to 37 8.3% in the
controls (NS). Stepwise multiple regression showed that basal
secretion (partial R2: 7%), in addition to pulsatile i-LH produc-
tion rate (partial R2: 20%) and half-life (partial R2: 22%),
contributed significantly to the variation in mean i-LH levels in
uremic patients (conservative treatment and dialysis groups
combined), but not in the subjects with normal or moderately
reduced renal function (transplant and control groups com-
bined).
The more pronounced increase in immunoreactive than bio-
active LH plasma concentrations was reflected in significantly
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Fig. 1. Examples of deconvolution analysis of bio-LH and i-H plasma concentration profiles. Upper panels depict 15-minute measured values
(data points) and fitted curves, and lower panels give deconvolution-estimated secretion rates. A. Control subject, male, pubertal stage PH4 04.
B. Patient on conservative treatment, male, PH4 G4. C. Dialysis patient, male, PH4 G4. Note significant baseline secretion of i-LH. D. Patient after
renal transplantation, male, PH4 04.
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Fig. 1. (Continued)
reduced bio-LHIi-LH ratios in the uremic patients. The mean
bio-LH/i-LH half-life ratio was 0.98 0.14 in the control, 1.05
0.24 (NS) in the transplant, 1.3 0.27 (NS) in the dialysis,
and 2.2 0.7 (P < 0.05 compared to control) in the conserva-
tive treatment group. The ratio of bio-LH/i-LH pulsatile pro-
duction rates was not significantly different in controls (1.57
0.4), patients on conservative treatment (1.14 0.2), on dialysis
(1.5 0.24) or after transplantation (2.2 0.22). However, the
bio-LH/i-LH ratio of total production rates was significantly
decreased in the dialysis (1.34 0.25) and conservative treat-
ment groups (1.22 0.30) compared to the control (2.51 0.56)
and transplant groups (2.56 0.41) (all differences P < 0.05).
Thus, the disproportionate increase of mean i-LH over bio-LH
concentrations in uremia appears to be due to the relative
increase in non-pulsatile i-LH secretion rather than to differ-
ences in the pulsatile secretory components or plasma half-lives
between i-LH and bio-LH.
Discussion
The present study is the first to assess the characteristics of
LH secretion and clearance in pubertal patients with CRF.
Endocrine investigations in such patients are complicated not
only by the variability induced by the pubertal process, but also
by differences in the degree of renal dysfunction when patients
in pre-endstage renal failure, on dialysis treatment and after
renal transplantation are considered. Hence, multicenter data
collection was required to obtain adequately sized comparable
samples of boys and girls at different stages of CRF, stratified
by pubertal stage.
The use of deconvolution analysis provides qualitatively and
quantitatively new information on the hypothalamo-pituitary-
gonadal axis in uremia. We observed a three- to fourfold
increase in the estimated plasma half-life of LH, a marked
reduction in the pulsatile LH secretory rate, and a relative
increase in apparent basal secretion of i-LH in the uremic
patients compared to healthy controls. In the patients after
renal transplantation, none of the LH secretory and clearance
characteristics was significantly different from control, suggest-
ing reversibility of the changes observed in the uremic patients
after recovery of renal function.
Usually elevated or high normal plasma LH concentrations
are found both in adults and children with CRF [4—7]. Although
a reduction of the metabolic clearance of LH has been demon-
strated previously in uremic animals [18, 19] and humans [4],
earlier investigations did not recognize the impact of accumu-
lation of intact LH, precursor molecules and/or incompletely
metabolized fragments on the observed pulsatile plasma con-
centrations of the hormone. Assuming no major change in LH
distribution volume in uremia, the increase in estimated endo-
genous LH half-life, measured here either by radioimmuno- or
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Fig. 1. (Continued)
bioassay, is in line with a marked decrease in metabolic
clearance rate (MCR) of LH. In quantitative terms, our esti-
mated three- to fourfold increase in LH half-life compares well
with the 3.3-fold decrease in MCR measured by Holdsworth,
Atkins and de Kretser using steady-state infusion of exogenous
LH (derived from pituitary extracts) in adult dialysis patients
[4]. The kidney is known to be a major catabolic site of many
polypeptide hormones [33]. LH is bound to, internalized by and
catabolized in the cells of the proximal convoluted tubules [34,
35]. This intrarenal catabolic pathway suggests that the MCR of
LH be directly determined by the functional renal mass. In-
deed, in the patients studied here, who encompassed a wide
spectrum from mild to severe renal insufficiency treated con-
servatively, by dialysis or renal transplantation, we were able to
demonstrate an inverse relationship between the plasma half-
life of bioactive LH and GFR (P < 0.0001). Of course, this
association does not exclude the possibility of any additional
alterations of the extrarena! MCR of LH in uremia, as docu-
mented for other hormones [36, 37].
Previous studies, using conventional techniques of peak
detection applied to plasma concentration profiles, reported a
decrease in detectable LH peak frequency in pubertal and adult
uremic patients [9—14] as well as in the uremic rat model [38].
However, pulsatile patterns in the hormone profiles of uremic
subjects are expected to be blurred by increased hormone
half-life [39]. The use of pulse analysis techniques that do not
allow for this confounding factor may be associated with an
increased risk for both false-positive and false-negative errors
in pulse detection. For the present analysis, we have estab-
lished the validity of the deconvolution method to detect LH
secretory episodes in uremia by applying it to synthetically
generated data series encompassing a wide range of plasma
half-lives. The method demonstrated high sensitivity and spec-
ificity, indicating its applicability in the particular metabolic
situation of uremia. In contrast to previous investigations using
conventional techniques of pulse detection, we also found no
decrease in either i-LH or bio-LH pulse frequency. In a parallel
study performed in adult dialysis patients, we found a normal
LH pulse frequency in six and an increased number of peaks in
three patients [40]. Thus, it appears likely that the earlier
impression of a decrease in LH pulse frequency was at least in
part due to methodological problems attributed to increased
plasma half-life.
In almost 50% of the subjects investigated in this study, LH
secretion was attributable not only to discrete episodic secre-
tory bursts, but also to a variable amount of non-pulsatile basal
secretion. The absolute quantities of pulsatile i-LH and bio-LH
secretion differed between the treatment and control groups,
and the relative contribution of basal secretion to the total
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production rate of i-LH and bio-LH appeared to be increased in
uremia.
The production rate of the pulsatile LH component was
independently affected by the pubertal state and the disease.
i-LH and bio-LH pulsatile secretion rates increased signifi-
cantly across pubertal stages, and, irrespective of gender and
the stage of puberty, were about 50% lower in dialysis patients
than in healthy controls. These findings are in agreement with
the 50% reduction in the pulsatile LH production rate we
observed in adult men on dialysis [40]. In the combined groups
of patients on conservative treatment and after transplantation
studied here, the reduction of pulsatile bio-LH secretion was
proportional (P = 0.008) to the degree of renal dysfunction as
expressed by GFR. In the absence of a change in LH secretory
burst frequency, the decrease in LH production rates was
caused by a distinct reduction in the mass of LH released per
secretory burst.
During healthy puberty, quantitative changes of LH secretion
are, at least according to studies using conventional methods of
pulse analysis, physiologically mediated by LH peak amplitude
modulation, probably in response to changes of the strength of
the GnRH pulse signal [24, 41, 42]. Therefore, the reduced LH
release per burst in the uremic patients may reflect endogenous
GnRH peaks of subnormal size and/or duration. In support of
this possibility, a reduction of spontaneous GnRH release by 40
to 50% has recently been demonstrated in uremic rats both in
vivo [43] and in hypothalamic explants [44]. Alternatively, the
gonadotroph response to GnRH may be compromized by
defects at the receptor or post-receptor level. Finally, the
release of LH from the gonadotroph cell could be altered.
Although several previous studies that did not correct for the
prolonged half-life of LH in uremia reported delayed and
blunted gonadotroph responses to stimulation with exogenous
GnRH [4, 6], we have recently demonstrated in uremic men that
the secretory response of LH to a submaximally effective
GnRH stimulus, measured by a highly sensitive and specific
immunoradiometric assay and quantitated by means of decon-
volution analysis, is not different from that observed in normal
subjects [40].
A remarkable finding in the present work was the relative
increase in apparent basal secretion of i-LH in uremic patients,
which was, if anything, accompanied by a slight decrease of
fractional basal bio-LH secretion. Until recently, relatively
little evidence for non-pulsatile LH release has been accumu-
lated in children, although there is preliminary evidence of
increased basal LH secretion in healthy aging men [45], in
young men treated with androgen receptor or GnRH antago-
nists [46, 47], and in postmenopausal women [48, 49]. There-
fore, it is of interest that we found an apparent tonic component
D
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Table 3. Deconvolution estimates of i-LH secretion and clearance
Half-life mm
Boys
Girls
No. of i-LH secretory bursts (per 11 hr)
Boys
Girls
Interburst interval pnin
Boys
Girls
Mass of i-LH secreted per burst JUt liter
Boys
Girls
Amplitude of i-LH secretory burst
IU/liter*,nin
Boys
Girls
i-LH secretory burst half-duration mm
Boys
Girls
i-LH pulsatile production rate IU/liter*I1 hr
Boys
Girls
i-LH basal secretion rate IUtliter*li hr
Boys
Girls
Total i-LH secretion rate IU/liter*11 hr
Boys
Girls
Conservative
treatment
3.9 1.0 (39
3.8 1.3 (28)b
5.3 3.3 (0)o
0n
0.34 0.12 (0.30)
0.90 0.34 (0.65)
0.2 0.05 (0.23)
0.7 0.38 (0.28)
of LH secretion in the many of the children studied. This
component was not related to sex or pubertal progress.
Since in uremic patients the contribution of basal secretion to
the total LH production was increased for i-LH but tended to be
decreased for bio-LH, the ratio between bio-LH and i-LH total
production rates was markedly shifted in favor of i-LH produc-
tion. This effect, rather than disproportionate changes in plasma
half-lives or pulsatile secretion, explains the reduced mean
bio-LH/i-LH ratios previously reported in dialysis patients by
ourselves [13] and others [11, 14].
There are several possible explanations for the relative
increase in apparent basal i-LH secretion in uremic patients.
First, a dissociation between LH immunoreactivity in classical
radioimmunoassays and biological activity may be caused by
insufficient specificity of polyclonal antibodies, including cross
reactivity with non-biologically active free a-subunit [50]. It is
also possible that in uremic patients increased plasma concen-
trations of other LH-like constituents occur that cross-react in
the RIA. Mathematically, this background immunological ac-
tivity can be construed as apparent basal release. Such putative
biologically inactive, but immunoreactive, LH-like molecules in
principle may either arise from constant leakage from the
gonadotroph, or may represent accumulated incompletely me-
tabolized LH fragments with very long half-lives. Indeed, the
latter phenomenon could contribute to the apparent increase in
basal secretion or suggest an even more delayed clearance
component in the deconvolution model [39].
The exact nature of the material in uremia detected by the
RIA but not the in vitro bioassay remains to be elucidated.
Discordant elevations of free a-subunit relative to LH concen-
trations in uremic serum have been reported [5, 51], and
enhanced a-subunit secretion from pituitary cells of uremic
animals has been demonstrated in vitro [52]. While cross
reactivity with free a-subunit in the assay used here was less
than 0.1% [27], there is evidence indicating that several inter-
mediates, differing in conformation and degree of glycosylation,
are synthesized prior to the formation of the final a-subunit [53].
These precursor molecules might accumulate and/or be subject
to higher antigenic recognition by the RIA LH antibody than
the final a-subunit itself. It is not known whether the metabolic
clearance rate of such glycoprotein precursors is lower than
that of the mature a-subunit, although the latter has a shorter
half-life than the complete LH molecule [54].
In summary, our multicenter data indicate that complex
changes occur in LH secretory and clearance dynamics in
uremic children. High normal plasma concentrations of bio-LH
and elevated plasma levels of i-LH are the final result of a large
increase in plasma half-life and a decrease in the mass and rate
of pulsatile secretion in proportion to the degree of loss of
functional renal mass. Concomitantly, there is a relative in-
crease in apparent basal secretion of immunoreactive, but not
bioactive, plasma LH-like constituents. The observed changes
in LH secretion and metabolism appear to be reversible after
successful renal transplantation.
The implications of the observed changes in LH secretion
Dialysis Transplantation
95 11 (95)a
174 32 (170)ab
7.2 1 (75)flS
6.5 0.2 (6.5)
98 14 (88)'
97 3 (95)
Controls
A 198 29 (201)b
217 53 (201)
NS 8±0.7(8)
6.2 0.8 (6)
84 14 (75)
NS 109 14 (107)
B 82 16 (77)
102 9 (1l5)bC
7.3 0.7 (7.5)
6.8 0.8 (6.5)
91 9 (90)
99 16 (95)
CAC 72 12 (56)54 4 (55)C
9.4 0.8 (9)
7.9 0.9 (8)
65 5 (66)
77 12 (83)
1 6 + 0.3 (l.5)ab 3.4 0.4 (3.0)a 20 0.3 (2.0)AB
3:0 1.0 (l.8r A 2.9 0.2 (28)ab AB 8:8 4.0 (58)b B
0.30 0,09 (0.29)s NS041 0.18 (0.24)
0.32 0.15 (0.l5) 0,73 0.41 (0.38)
30 15 (ll) A 6.0 1.5 (5.7)
19 8 (14)' 7 1.4 (7)
27 7.3 (22)
24 7.7 (l9) A 12 1.4 (10)B 18 6.3 (23)
s 8.6 5.3 (0)N 10.6 7.3 (0)
21 5.9 (15)NS 29 6.8 (30)
32 6.2 (31)
24 7.7 (l9)
B 4.3 (11)11 7.4 (4.7)
24 1.5 (23)A 20 2.7 (l9)
2.6 2.6 (0)
1.3 1.3 (0)
27 2.6 (26)
21 2.2 (22)a
AB
B
12 3.9 (8.7)AB 16 1.9 (18)
B 20±3(19)A 72 31 (42)b
0
6.0 5.9 (5.6)
20 3 (19)
82 31 (48)b
Data are mean SEM (median). Letters indicate significant differences between columns within each row, groups with common letters not
differing significantly. Superscript letters give significances for sex subgroups; capital letters for sexes combined. NS means no significant
differences within a row. Significance level is P < 0.05.
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Table 4. Deconvolution estimates of bio-LH secretion and clearance
Conservative
treatment Dialysis Transplantation Controls
Half-life mm
Boys
Girls
260 72 (210)A
205 55 (203) A
204 34 (197)ab
379 68 (310)b A
88 15 (86)88 9 (84) B 63 14 (58Y56 12 (53)C B
No. of bio-LH secretory bursts (per 11 hr)
Boys
Girls
7.3 0.8 (6.5)s
5.2 0.9 (55)S NS
1.0 (6.5)
6.2 0.5 (6.5)
8 0.9 (6.5)
6 0.9 (7.5) 6 0.9 (5)7 1.1 (7)
Interburst interval mm
Boys
Girls
99 12 (88)S
99 7.7 (95)nlS NS 11(96)118 17 (102)
103 14(107)
91 10(95)
118 18(118)
115 19(105)
Mass of bio-LH secreted per burst lU/liter
Boys
Girls
3.2 0.6 (3.2)a
6.6 3.6 (3.l)Is A
1.2 (2.1)a
2.9 0.8 (2.6) A
7.6 1.2 (7.6)t
5.4 0.8 (5.8) B
8.1 2.2 (8•8)b
5.7 1.3 (5.1) B
Amplitude of bio-LH secretory burst JUl
liter*mnin
Boys 0.80 0.65 (0.18)" tD 0.29 0.12 (0.19) A 0.60 0.14 (0.63) 0.52 0.17 (0.50)
Girls 3.2 2.9 (0.36)"" 0.25 0.12 (0.16)a 0.68 0.21 (0.42)"" 1.2 0.28 (0.99)'
Bio-LH secretory burst half-duration mm
Boys
Girls
21 5.9 (20)"'
28 8.0 (29)" 15 5.0 (8.8)14 5.0 (10)"" A13
15 3.3 (14)
9.5 1.6 (9.5)"" tW
20 6.5 (14)
s4 1.7 (42)b
Bio-LH pulsatile production rate
IU/liter*min*1l hr
Boys
Girls
21 3.3 (23)"
35 17 (21)"' A
22 5.7 (18)"
18 5.8 (15) A
48 5.1 (47)b
45 9.9 (45) B
48 16 (39)ab
39 10 (27) B
Bio-LH 'basal secretion' rate lUIliter*11 hr
Boys
Girls
4.6 3.3 (0)"'
13 13 (Ø)S NS
6.6 5.0 (0)
0
22 17 (0)
2.4 2.4 (0)
31 13 (26)
46 25 (5.3)
Total bio-LH production rate JUl liter*11
hr
Boys
Girls
26 4.2 (27)"'
48 31 (21)"
A 29 7.0 (31)
18 5.8 (15)" A
70 20 (57)
48 8.9 (45)ab
,, 77 25 (68)
88 26 (51)"
Data are mean SEM (median). Letters indicate significant differences between columns within each row, groups with common letters not being
significantly. Superscript letters give significances for sex subgroups; capital letters for sexes combined. NS means no significant differences within
a row. Significance level is P < 0.05.
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Fig. 2. Relationship between GFR and estimated plasma half-life of
bio-LH. Open circles represent patients on dialysis, closed circles
patients on conservative treatment, and squares patients after renal
transplantation. Dialysis patients, in whom GFR usually varied be-
tween 5 and 10 mI/mm * 1.73 m2, were abitrarily entered as 7 mu
mm * 1.73 m2. Exponential regression line is shown as derived from
pooled groups of patients on conservative treatment and after renal
transplantation.
and clearance on the functional integrity of the hypothalamo-
pituitary-gonadal axis will require further study. For example, it
is not yet clear whether the reduction of pulsatile LH secretion
rate indicates uremic "damage" to the hypothalamic GnRH
pulse generator, or rather results from "physiological" auto-
crine down-regulation in response to the inevitable increase in
plasma LH half-life secondary to reduced renal elimination. If
the LH production rate was not decreased, more marked
accumulation of LH would occur. If stimulation of the gonads is
dependent on mean circulating LH levels rather than on char-
acteristics of the secretory pattern, and since the half-life of
bioactive LH isoforms appears to be increased in proportion to
that of total LH immunoreactivity, the secretory demand may
be reduced in renal failure. On the other hand, high normal or
elevated concentrations of LH were associated with low normal
plasma testosterone levels in this and other studies [7], and the
gonadal response to stimulation by LH/hCG has been demon-
strated to be reduced in uremic animals [55, 56], boys [8] and
adult men [4, 7]. Thus, despite LH "sparing" due to reduced
elimination in uremia, the rate of pulsatile secretion may still be
insufficient to provide adequate gonadal stimulation in this
impeded environment, resulting in pubertal delay or arrest and
clinical hypogonadism. In uremic pubertal females, the altered
secretory pattern of LH may perturb the emergence of the
physiological periodical changes in LH pulsatility required for
regular ovarian cycles, contributing to delayed menarche, re-
duced fertility and menstrual disorders.
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